OptiNose rises after sinusitis therapy succeeds in second study

OptiNose

13/06/2022 12:29

** Shares of OptiNose Inc  OPTN.O  rise 10.8% to $2.05
premarket 
    ** Co says its drug-device combination Xhance significantly
relieved symptoms of chronic sinusitis and reduced inflammation
compared with a placebo in a late-stage study  urn:newsml:reuters.com:*:nGNX48xX7Z
    ** Xhance, already approved to treat nasal polyps, met the
main goals of a separate late-stage sinusitis study in March
 urn:newsml:reuters.com:*:nL3N2VA342
    ** OPTN estimates that chronic sinusitis, which has no
approved treatments, is diagnosed 10 times more often than nasal
polyps in the United States  
    ** Co earned $14.8 mln from Xhance sales in Q1 
    ** OPTN shares are up 14.2% YTD 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))